Rockville, Maryland — September 23, 2026 — The global cryopreservation & fertilization media market is valued at USD 860.0 million in 2026 and is projected to reach USD 1,497.1 million by 2036, expanding at a 5.7% CAGR during the 2026–2036 forecast period, according to Fact.MR. The market reached USD 813.6 million in 2025. Growth is being supported by increasing frozen embryo transfer activity, egg and embryo banking, ready-to-use laboratory formulations, research repositories, and animal-breeding applications. The Human Fertilisation and Embryology Authority reported that frozen transfers accounted for 45% of embryo transfers in the United Kingdom in 2023.

Demand for preservation and warming media is linked to repeated laboratory procedures rather than equipment ownership. The U.S. Centers for Disease Control and Prevention recorded 184,423 banking cycles among assisted reproductive technology cycles in 2022, creating recurring requirements for appropriate formulations and handling protocols.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=5707

Global Segment Leaders

Product — Cryopreservation Media: 41.9% share in 2026. Repeated freezing requirements for germ cells, embryos, and other viable biological material support continued consumption of preservation media.
Form — Liquid Media: 53.7% share in 2026. Liquid formulations can be dispensed directly within established laboratory workflows, while ready-to-use products can reduce preparation steps.
Application — Human Assisted Reproduction: 38.6% share in 2026. Fertilization, embryo storage, and subsequent warming create several media requirements within a single treatment pathway.
End Use — IVF Centers: 44.8% share in 2026. IVF centers concentrate fertilization and embryo-handling activity and therefore require recurring purchases across multiple media categories.
Technology — Vitrification Technology: 47.5% share in 2026. Vitrification is used in oocyte and embryo preservation pathways and is paired with specific warming procedures.
Country-Level Performance

Country

CAGR

Key Growth Driver

Germany

6.6%

The German IVF Register's 2024 yearbook documents IVF, ICSI, and cryotransfer activity, highlighting treatment sequences involving fresh treatment, storage, and subsequent transfer.

Brazil

6.0%

Anvisa's SisEmbrio system records information from assisted-reproduction centers and germ-cell and tissue banks, providing a framework for tracking procedures that consume media.

USA

5.4%

The CDC reported 435,426 ART cycles across 457 reporting U.S. clinics in 2022, indicating the scale of laboratory activity underlying media procurement.

UK

4.9%

HFEA data connect increased use of single-embryo transfer with subsequent frozen-transfer activity, creating additional solution requirements across laboratory stages.

Japan

4.3%

The Japan Society of Obstetrics and Gynecology's national ART report for 2023 separately tracks fresh treatment and frozen-thawed embryo-transfer cycles, supporting demand for application-specific media.

Regional Context

Germany and Brazil are the faster-growing country markets among those profiled by Fact.MR, with projected CAGRs of 6.6% and 6.0%, respectively. Germany's established IVF laboratory base and documented cryotransfer activity support recurring purchases, while Brazil's assisted-reproduction centers require dependable formulation availability, usable shelf life, and compliant storage throughout distribution.

The United States, United Kingdom, and Japan record CAGRs of 5.4%, 4.9%, and 4.3%, respectively. U.S. demand is supported by the scale of ART activity and egg and embryo banking; the UK benefits from increasing frozen-transfer activity; and Japan has an established frozen-thawed embryo-transfer workflow within specialist reproductive laboratories.

The broader report covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East & Africa, with analysis spanning 30+ countries. Country-level CAGR analysis is specifically provided for Germany, Brazil, the USA, the UK, and Japan.

Competitive Landscape

Key companies profiled by Fact.MR include Cooper Surgical, Vitrolife AB, Cook Medical, FUJIFILM Irvine Scientific, Kitazato Corporation, Genea Biomedx, GYNEMED GmbH & Co. KG (A Hamilton Thorne Company), FERTIPRO NV, Nidacon International AB, and Microm Ltd. The report also identifies Nexpring Health as the platform under which several relevant reproductive-health product businesses now operate.

A notable development occurred in June 2025, when Nexpring Health announced completion of its acquisition of FUJIFILM Irvine Scientific's ART and cytogenetics product lines. The report also notes that Microm UK Limited was acquired by Calibre Scientific in 2024, expanding Calibre Scientific's assisted reproductive technology portfolio.

The competitive environment includes broad laboratory portfolios as well as specialized providers. Genea Biomedx combines media with laboratory equipment and workflow offerings, while FERTIPRO and Nidacon focus on formulations for specific reproductive procedures.

Explore More Related Studies Published by Fact.MR Research

Omics Lab Services Market

Antimicrobial PPE Market

Color Correcting Glasses Market

Intraoral X-Ray Market

About Fact.MR

Fact.MR is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, pharmaceuticals, and biotechnology.

For more information on the full report, visit: Cryopreservation & Fertilization Media Market